<< Back To Search

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

Notify the Multiple Myeloma Research Foundation you are interested in this trial
NCT05372354
Age 18 +
Sex Both
Phase Phase 1, Phase 2
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on using a combination of therapies to improve patient outcomes. Here are some key details about the study:
  • The treatment involves a combination of existing therapies and new methods to enhance effectiveness.
  • It aims to target the cancer cells more precisely, potentially leading to better results.
  • Patients will be monitored closely to assess how well the treatment works and to identify any side effects.
  • This study is unique because it combines different treatment strategies that have not been used together before.
  • Researchers hope that this approach will lead to improved survival rates and quality of life for patients.
Overall, this study represents an innovative effort to tackle a challenging condition by using a multi-faceted treatment strategy that could offer new hope to patients.
Third Opinion AI Generated Synopsis

Trial Summary
The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).
from ClinicalTrials.gov

Locations & Contact

Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: